Sugi Predict

Sugi Predict / Compounds / SCHEMBL233208

SCHEMBL233208

SCHEMBL233208

O=C(Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O)c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.72
▸ SLC29A1 Q99808 2/20 0.72
▸ TSHR P16473 2/20 0.72
▸ NFKB1 P19838 2/20 0.72
▸ THPO P40225 2/20 0.72
▸ ALDH1A1 P00352 1/20 0.72
▸ GLA P06280 1/20 0.72
▸ PMP22 Q01453 1/20 0.72
▸ SMN1; SMN2 Q16637 1/20 0.72
▸ NPC1 O15118 1/20 0.72
▸ NPY1R P25929 1/20 0.72
▸ HTT P42858 1/20 0.72
▸ NPY2R P49146 1/20 0.72
▸ RAB9A P51151 1/20 0.72
▸ RXFP1 Q9HBX9 1/20 0.72
▸ CYP1A2 P05177 1/20 0.72
▸ MAPK1 P28482 1/20 0.72
▸ CYP2C19 P33261 1/20 0.72
▸ ADORA3 P0DMS8 4/20 0.69
▸ TP53 P04637 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29617913 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL27986516 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL17889837 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL313413 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL6909853 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL17301042 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL9945526 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL19485512 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL233209 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL21953578 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1089 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4622982-A1 METHODS OF SYNTHESIZING A TARGETING LIGAND-CONJUGATED NUCLEOTIDE PHOSPHORAMIDITE Eli Lilly and Company (US) 2025-10-01 — — EP claimed
EP-4606903-A1 METHOD FOR ENZYMATIC SYNTHESIS OF NUCLEOSIDE CONTAINING PROTECTING GROUP, AND COMPOSITION Asymchem Life Science (Tianjin) Co., Ltd (CN) 2025-08-27 — — EP claimed
WO-2024112877-A1 METHODS OF SYNTHESIZING A TARGETING LIGAND-CONJUGATED NUCLEOTIDE PHOSPHORAMIDITE ELI LILLY AND COMPANY (US) 2024-05-30 — — WO claimed
WO-2024082545-A1 METHOD FOR ENZYMATIC SYNTHESIS OF NUCLEOSIDE CONTAINING PROTECTING GROUP, AND COMPOSITION 凯莱英生命科学技术(天津)有限公司 2024-04-25 — — WO claimed
CN-117338961-A PD-L1 targeting molecular probe and preparation method and application thereof 江南大学 2024-01-05 — — CN claimed
CN-116064703-A Method and composition for enzymatic synthesis of nucleosides containing protecting groups 凯莱英生命科学技术(天津)有限公司 2023-05-05 — — CN claimed
US-20220048941-A1 MODIFIED NUCLEOSIDE PHOSPHORAMIDITES Janssen Biopharma, Inc. (US) 2022-02-17 — — US claimed
US-11180524-B2 Modified nucleoside phosphoramidites Janssen Biopharma, Inc. (US) 2021-11-23 — — US claimed
CN-112341509-A Preparation method of N6-benzoyl adenosine 新乡瑞诚科技股份有限公司 2021-02-09 — — CN claimed
US-20200255468-A1 MODIFIED NUCLEOSIDE PHOSPHORAMIDITES Janssen Pharmaceuticals, Inc. 2020-08-13 — — US claimed
WO-2019053659-A1 MODIFIED NUCLEOSIDE PHOSPHORAMIDITES ALIOS BIOPHARMA, INC. (US) 2019-03-21 — — WO claimed
CN-108339120-A Application of protein kinase A activator in preparing medicine for treating diseases related to platelet quantity reduction 苏州大学 2018-07-31 — — CN claimed
EP-1379536-A4 BUILDING BLOCKS FOR THE SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES ISIS PHARMACEUTICALS INC (US) 2007-07-25 — — EP claimed
WO-2006038865-A1 NUCLEOTIDE DERIVATIVES FOR THE TREATMENT OF TYPE 2 DIABETES AND OTHER DISORDERS BETAGENON AB (SE) 2006-04-13 — — WO claimed
CN-1500094-A Building blocks for solution phase synthesis of oligonucleotides ISIS药物公司 2004-05-26 — — CN claimed
US-20040096947-A1 Building blocks for the solution phase synthesis of oligonucleotides SANGHVI YOGESH S (US) 2004-05-20 — — US claimed
EP-1379536-A1 BUILDING BLOCKS FOR THE SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES ISIS Pharmaceuticals, Inc. (US) 2004-01-14 — — EP claimed
US-6677120-B2 PREFERENTIAL DEPROTECTION OF A 3',5'-DI-O- LEVULINYL NUCLEOSIDE; OBTAIN 3',5'-DI-O-LEVULINYL NUCLEOSIDE, INCUBATE WITH LIPASE, RECOVER 3'-O-LEVULINYL AND 5'-O-LEVULINYL NUCLEOSIDE ISIS PHARMACEUTICALS, INC. 2004-01-13 — — US claimed
WO-2002079215-A1 BUILDING BLOCKS FOR THE SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 2002-10-10 — — WO claimed
US-20020142307-A1 Building blocks for the solution phase synthesis of oligonucleotides IONIS PHARMACEUTICALS, INC. 2002-10-03 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200255468-A1 MODIFIED NUCLEOSIDE PHOSPHORAMIDITES PNP, MTAP, NT5C3B LMNA 435/4885SLC29A1 19/4885TSHR 4209/4885
US-11180524-B2 Modified nucleoside phosphoramidites PNP, MTAP, NT5C3B LMNA 435/4885SLC29A1 19/4885TSHR 4209/4885
US-20220048941-A1 MODIFIED NUCLEOSIDE PHOSPHORAMIDITES PNP, TYMP, NSUN2 LMNA 1464/4885SLC29A1 123/4885TSHR 731/4885
US-20040096947-A1 Building blocks for the solution phase synthesis of oligonucleotides RNGTT, TYMS, POLB LMNA 546/4885SLC29A1 532/4885TSHR 3384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.